aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Saturday . The stock traded as high as $6.44 and last traded at $5.99, with a volume of 5069655 shares traded. The stock had previously closed at $5.79.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Wells Fargo & Company lifted their target price on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, June 20th. HC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $20.20.
Read Our Latest Stock Analysis on ATYR
aTyr Pharma Stock Down 8.2%
The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. The stock has a market cap of $466.36 million, a PE ratio of -6.47 and a beta of 0.89. The business has a 50 day moving average price of $4.82 and a 200 day moving average price of $3.94.
aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. Equities research analysts expect that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.
Institutional Investors Weigh In On aTyr Pharma
A number of institutional investors have recently modified their holdings of ATYR. Group One Trading LLC purchased a new stake in aTyr Pharma during the 4th quarter worth about $26,000. Victory Capital Management Inc. purchased a new stake in aTyr Pharma during the 4th quarter worth about $37,000. Y Intercept Hong Kong Ltd purchased a new stake in aTyr Pharma during the 1st quarter worth about $38,000. Raymond James Financial Inc. purchased a new stake in aTyr Pharma during the 4th quarter worth about $39,000. Finally, XTX Topco Ltd purchased a new stake in aTyr Pharma during the 4th quarter worth about $40,000. 61.72% of the stock is owned by institutional investors and hedge funds.
aTyr Pharma Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
Before you consider aTyr Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.
While aTyr Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access